27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Biotech stocks came under pressure last week despite two FDA approvals coming through. The FDA approved SAGE Therapeutics Inc (NASDAQ:SAGE)'s drug to treat postpartum depression and Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)'s sleep disorder drug.
Biogen Inc (NASDAQ:BIIB)'s Alzheimer's drug disappointment contributed to some of the negativity.
Looking ahead to the unfolding week, here are a few catalysts a biotech investor needs to be mindful about.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Conferences
- Endo 2019 – March 23-26, in New Orleans, Lousisana
- 2nd Annual Congress on Diabetes and its Complications - March 25-26, in Hong Kong
- 11th World Congress and Expo on Cell & Stem Cell Research - March 25-26, in Orlando, Florida
- 14th International Conference on Alzheimers and Parkinson's Diseases - March 26-31, in Lisbon, Portugal
- KBC Securities Biotech and Healthcare Conference – March 26-27, in New York
- 3rd Annual Gene Therapy For Rare Disorders – March 26-28, in Boston, Massachusetts
- 5th World Heart Congress - March 27-28, in Sydney, Australia
- Cold Spring Harbor Conference on RNA and Oligonucleotide Therapeutics -March 27-30, in Cold Spring Harbor, New York
See Also: Analysts Digest Biogen's Alzheimer's Disappointment: 'There Isn't Much To Be Excited About'
PDUFA Dates
The FDA is set to rule Sunday on Recro Pharma Inc (NASDAQ:REPH)'s NDA intravenous (IV) meloxicam, which is being evaluated for the management of moderate to severe pain.
Novartis AG (NYSE:NVS)'s NDA for oral, once-daily siponimod, or BAF312, for secondary progressive multiple sclerosis, or SPMS, in adults.
Clinical Trial Results
Ascendis Pharma A/S (NASDAQ:ASND) will present the already-released Phase 3 data for TransCon hGH, its treatment candidate for growth hormone deficiency in children Sunday at ENDO 2019.
Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) is scheduled to present Monday already-released Phase 2 data for its post-bariatric hypoglycemia treatment candidate Avexitide at ENDO 2019.
Fibrocell Science Inc (NASDAQ:FCSC) will release updated Phase 1/2 data for FCX-007, its treatment candidate for recessive dystrophic epidermolysis bullosa.
Companies With Q1 Release Schedules
Proteostasis Therapeutics Inc (NASDAQ:PTI) – full Phase 1 data for PTI-428 + PTI-801 + PTI-808, Phase 1 data for the fourth cohort (PTI-801 and PTI-808) and Phase 1 data for PTI-801 + Symdeko (all combos are evaluated for cystic fibrosis)
Supernus Pharmaceuticals Inc (NASDAQ:SUPN) – final trial data from a Phase 3 study of SPN-812 (ADHD)
FibroGen Inc (NASDAQ:FGEN) – initial Phase 2 data for FG-3019 (Duchenne muscular dystrophy)
Want Private Access to Benzinga Analyst?
Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.
Insys Therapeutics Inc (NASDAQ:INSY) – Phase 2 data for Cannabidiol (refractory childhood absence epilepsy)
(Note: This is not a complete list.)
See Also: Nevro's C-Suite, Board Changes Should 'Mark The Turnaround Of The Organization,' BMO Says In Upgrade
Earnings
Monday, March 25
- Yield10 Bioscience Inc (NASDAQ:YTEN) (after the market close)
- Cesca Therapeutics Inc (NASDAQ:KOOL) (after the market close)
- aTyr Pharma Inc (NASDAQ:LIFE) (after the market close)
Tuesday, March 26
- Onconova Therapeutics Inc (NASDAQ:ONTX) (before the market open)
- PhaseBio Pharmaceuticals Inc (NASDAQ:PHAS) (after the market close)
Wednesday, March 27
- Affimed NV (NASDAQ:AFMD) (before the market open)
- Eyenovia Inc (NASDAQ:EYEN) (before the market open)
- Fibrocell Science Inc (NASDAQ:FCSC) (before the market open)
- Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) (after the market close)
Thursday, March 28
- Tricida Inc (NASDAQ:TCDA) (before the market open)
- Achaogen Inc (NASDAQ:AKAO) (after the market close)
- Biocept Inc (NASDAQ:BIOC) (after the market close)
- Vermillion, Inc. (NASDAQ:VRML) (after the market close)
- Capricor Therapeutics Inc (NASDAQ:CAPR) (after the market close)
IPO
Genfit, a biopharma company focusing on developing therapies and diagnostic solutions for metabolic and liver-related diseases, is set to offer 5 million shares in an IPO. The shares are to be listed on the Nasdaq under the ticker symbol GNFT.
Precision Biosciences, a genome editing biotech, has filed to offer 7.9 million shares in an IPO, with an estimated price range of $15-$17. The shares of the company will be listed on the Nasdaq under the ticker symbol DTIL.
IPO Quiet Period Expiry
Kaleido Biosciences Inc (NASDAQ:KLDO)
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.